Show simple item record

dc.contributor.authorYshii, Lidia
dc.contributor.authorPasciuto, Emanuela
dc.contributor.authorBielefeld, Pascal
dc.contributor.authorMascali, Loriana
dc.contributor.authorLemaitre, Pierre
dc.contributor.authorMarino, Marika
dc.contributor.authorDooley, James
dc.contributor.authorKouser, Lubna
dc.contributor.authorVerschoren, Stijn
dc.contributor.authorLagou, Vasiliki
dc.contributor.authorKemps, Hannelore
dc.contributor.authorGervois, Pascal
dc.contributor.authorde Boer, Antina
dc.contributor.authorBurton, Oliver T
dc.contributor.authorWahis, Jérôme
dc.contributor.authorVerhaert, Jens
dc.contributor.authorTareen, Samar HK
dc.contributor.authorRoca, Carlos P
dc.contributor.authorSingh, Kailash
dc.contributor.authorWhyte, Carly E
dc.contributor.authorKerstens, Axelle
dc.contributor.authorCallaerts-Vegh, Zsuzsanna
dc.contributor.authorPoovathingal, Suresh
dc.contributor.authorPrezzemolo, Teresa
dc.contributor.authorWierda, Keimpe
dc.contributor.authorDashwood, Amy
dc.contributor.authorXie, Junhua
dc.contributor.authorVan Wonterghem, Elien
dc.contributor.authorCreemers, Eline
dc.contributor.authorAloulou, Meryem
dc.contributor.authorGsell, Willy
dc.contributor.authorAbiega, Oihane
dc.contributor.authorMunck, Sebastian
dc.contributor.authorVandenbroucke, Roosmarijn E
dc.contributor.authorBronckaers, Annelies
dc.contributor.authorLemmens, Robin
dc.contributor.authorDe Strooper, Bart
dc.contributor.authorVan Den Bosch, Ludo
dc.contributor.authorHimmelreich, Uwe
dc.contributor.authorFitzsimons, Carlos P
dc.contributor.authorHolt, Matthew G
dc.contributor.authorListon, Adrian
dc.date.accessioned2022-06-08T15:00:55Z
dc.date.available2022-06-08T15:00:55Z
dc.date.issued2022-06
dc.date.submitted2022-03-01
dc.identifier.issn1529-2908
dc.identifier.others41590-022-01208-z
dc.identifier.other1208
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/337904
dc.description.abstractThe ability of immune-modulating biologics to prevent and reverse pathology has transformed recent clinical practice. Full utility in the neuroinflammation space, however, requires identification of both effective targets for local immune modulation and a delivery system capable of crossing the blood-brain barrier. The recent identification and characterization of a small population of regulatory T (Treg) cells resident in the brain presents one such potential therapeutic target. Here, we identified brain interleukin 2 (IL-2) levels as a limiting factor for brain-resident Treg cells. We developed a gene-delivery approach for astrocytes, with a small-molecule on-switch to allow temporal control, and enhanced production in reactive astrocytes to spatially direct delivery to inflammatory sites. Mice with brain-specific IL-2 delivery were protected in traumatic brain injury, stroke and multiple sclerosis models, without impacting the peripheral immune system. These results validate brain-specific IL-2 gene delivery as effective protection against neuroinflammation, and provide a versatile platform for delivery of diverse biologics to neuroinflammatory patients.
dc.languageen
dc.publisherSpringer Science and Business Media LLC
dc.subjectArticle
dc.subject/631/250/371
dc.subject/631/250/251
dc.subject/631/250/127/1213
dc.subject/631/250/1619/554/1898/1271
dc.subjectarticle
dc.titleAstrocyte-targeted gene delivery of interleukin 2 specifically increases brain-resident regulatory T cell numbers and protects against pathological neuroinflammation.
dc.typeArticle
dc.date.updated2022-06-08T15:00:53Z
prism.endingPage891
prism.issueIdentifier6
prism.publicationNameNat Immunol
prism.startingPage878
prism.volume23
dc.identifier.doi10.17863/CAM.85311
dcterms.dateAccepted2022-04-11
rioxxterms.versionofrecord10.1038/s41590-022-01208-z
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidPasciuto, Emanuela [0000-0002-5391-9585]
dc.contributor.orcidMarino, Marika [0000-0001-6773-6176]
dc.contributor.orcidDooley, James [0000-0003-3154-4708]
dc.contributor.orcidVerschoren, Stijn [0000-0001-6733-3481]
dc.contributor.orcidKemps, Hannelore [0000-0001-9248-1697]
dc.contributor.orcidGervois, Pascal [0000-0002-8320-1320]
dc.contributor.orcidBurton, Oliver T [0000-0003-3884-7373]
dc.contributor.orcidSingh, Kailash [0000-0002-6771-7757]
dc.contributor.orcidWhyte, Carly E [0000-0001-6556-6855]
dc.contributor.orcidCallaerts-Vegh, Zsuzsanna [0000-0001-9091-2078]
dc.contributor.orcidDashwood, Amy [0000-0002-4340-377X]
dc.contributor.orcidGsell, Willy [0000-0001-7334-6107]
dc.contributor.orcidVandenbroucke, Roosmarijn E [0000-0002-8327-620X]
dc.contributor.orcidListon, Adrian [0000-0002-6272-4085]
dc.identifier.eissn1529-2916
pubs.funder-project-idEC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) (TreatBrainDamage, TissueTregs, AstroFunc)
pubs.funder-project-idRCUK | Biotechnology and Biological Sciences Research Council (BBSRC) (BBS/E/B/000C0428, BBS/E/B/000C0427)
pubs.funder-project-idInternationale Stichting Alzheimer Onderzoek (ISAO) (20190032)
pubs.funder-project-idFondation Thierry Latran (Thierry Latran Foundation) (SOD-VIP)
cam.issuedOnline2022-05-26


Files in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record